Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS)

• Main Authors: Victor Pera (Author), Guy G. Brusselle (Author), Sebastian Riemann (Author), Jan A. Kors (Author), Erik M. Van Mulligen (Author), Rowan Parry (Author), Marcel de Wilde (Author), Peter R. Rijnbeek (Author), Katia M. C. Verhamme (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Monoclonal antibodies (mAbs) targeting immunoglobulin E (IgE) [omalizumab], type 2 (T2) cytokine interleukin (IL) 5 [mepolizumab, reslizumab], IL-4 Receptor (R) α [dupilumab], and IL-5R [benralizumab]), improve quality of life in patients with T2-driven inflammatory diseases. However,...